NCT05046665View on ClinicalTrials.gov

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

August 9, 2022

Study Completion Date

August 9, 2022

Conditions
Urothelial Carcinoma
Interventions
DRUG

89Zr-Girentuximab

Administration of 89Zr-girentuximab as per protocol.

Trial Locations (1)

6150

Fiona Stanley Hospital, Murdoch

All Listed Sponsors
collaborator

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY

lead

South Metropolitan Health Service

OTHER_GOV